Donald Harvey, PharmD, BCOP, FCCP, FHOPA, from the Winship Cancer Institute, Atlanta, GA, gives a pharmacist’s perspective on the challenges of using biomarkers in immunotherapy. Using PD-1 and PD-L1 as examples, Dr Harvey discusses the challenge in interpreting biomarker results to make clinical decisions and identify which patients will benefit from a given therapy., Dr Harvey shares insights from the audience discussions on the subject at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
- The challenges of using biomarkers for immunotherapy ( Download)
- Challenges With Finding Biomarkers for Immunotherapy ( Download)
- Immuno-Oncology Biomarker Update and Testing Challenges ( Download)
- The Present and the Future of Cancer Immunotherapy Biomarkers ( Download)
- Pharmacist's advice on biomarkers for immunotherapy ( Download)
- Circulating Tumor DNA as an Immunotherapy Biomarker ( Download)
- Immunotherapy Biomarkers ( Download)
- Role of Genomics in Identifying Biomarkers for Response and Resistance to Anti-Cancer Immunotherapy ( Download)
- Predictive biomarkers for immunotherapy in upper GI cancers ( Download)
- Blood-based biomarkers for immunotherapy in NSCLC ( Download)
- Biomarkers in Cancer Immunotherapy: How Much Do They Matter ( Download)
- Progress in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors ( Download)
- Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment ( Download)
- Velcheti Biomarkers for Immunotherapy Is There Anything Better Than PDL1 ( Download)
- Emerging immunotherapy biomarkers for predicting systemic therapy in HCC ( Download)
